PolyBio Research Foundation
@polybiorf.bsky.social
501(c)3 transforming how #LongCovid, #ME/CFS & Lyme+ are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.
January 12, 2026 at 10:58 PM
Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
January 12, 2026 at 10:58 PM
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
January 2, 2026 at 6:26 PM
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.
January 1, 2026 at 12:26 AM
To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.
No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown
#polybio2026countdown
December 31, 2025 at 8:27 PM
No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown
#polybio2026countdown
PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.
December 30, 2025 at 10:51 PM
PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.
No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.
December 29, 2025 at 10:13 PM
No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.
No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS.
#polybio2026countdown
#polybio2026countdown
December 28, 2025 at 10:20 PM
No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS.
#polybio2026countdown
#polybio2026countdown
2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic.
#polybio2026countdown
#polybio2026countdown
December 28, 2025 at 12:20 AM
2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic.
#polybio2026countdown
#polybio2026countdown
One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
December 26, 2025 at 8:28 PM
One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
December 23, 2025 at 12:20 AM
A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.
December 20, 2025 at 8:29 PM
Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.
You can help PolyBio ensure that our impactful work continues by pledging to be a “PolyBio Persister.” Those in the Persister Program make a 3-year commitment to supporting our research on infection-associated chronic illness. Consider joining today!
polybio.org/wp-content/u...
polybio.org/wp-content/u...
December 19, 2025 at 7:21 PM
You can help PolyBio ensure that our impactful work continues by pledging to be a “PolyBio Persister.” Those in the Persister Program make a 3-year commitment to supporting our research on infection-associated chronic illness. Consider joining today!
polybio.org/wp-content/u...
polybio.org/wp-content/u...
Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown
December 19, 2025 at 7:21 PM
Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown
Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
December 18, 2025 at 11:37 PM
Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵
Today at the HHS Invisible Illness roundtable: Dr. Amy Proal (PolyBio President & Scientific Director of the CoRE clinic) with 60 Degrees Pharma CEO, Dr. Geoffrey Dow. Dr.s Proal & Dow were part of the crucial discussion to address gaps in Lyme disease diagnostics & treatment.
December 17, 2025 at 12:27 AM
Today at the HHS Invisible Illness roundtable: Dr. Amy Proal (PolyBio President & Scientific Director of the CoRE clinic) with 60 Degrees Pharma CEO, Dr. Geoffrey Dow. Dr.s Proal & Dow were part of the crucial discussion to address gaps in Lyme disease diagnostics & treatment.
2/Read the paper here: pubmed.ncbi.nlm.nih.gov/39947217/
December 16, 2025 at 4:42 PM
2/Read the paper here: pubmed.ncbi.nlm.nih.gov/39947217/
One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown
#polybio2026countdown
December 16, 2025 at 4:42 PM
One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown
#polybio2026countdown
We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown
December 15, 2025 at 4:24 PM
We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown
We are excited to announce that PolyBio core team members Dr. Amy Proal & Dr. David Putrino are leading a clinical trial of tafenoquine for treatment of chronic babesiosis, in partnership with 60 Degrees Pharma. The trial will take place at Mount Sinai’s CoRE clinic & will treat up to 100 patients.
December 14, 2025 at 10:40 PM
We are excited to announce that PolyBio core team members Dr. Amy Proal & Dr. David Putrino are leading a clinical trial of tafenoquine for treatment of chronic babesiosis, in partnership with 60 Degrees Pharma. The trial will take place at Mount Sinai’s CoRE clinic & will treat up to 100 patients.
2/ Circulating spike protein, potentially leaking from SARS-CoV-2 reservoirs, was detected in blood from a subset of children. We are supporting a clinical trial in Long COVID children, to test if the drug Larazotide can reduce gut barrier permeability, thereby stopping spike leakage into blood.
December 12, 2025 at 7:04 PM
2/ Circulating spike protein, potentially leaking from SARS-CoV-2 reservoirs, was detected in blood from a subset of children. We are supporting a clinical trial in Long COVID children, to test if the drug Larazotide can reduce gut barrier permeability, thereby stopping spike leakage into blood.
1/ PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.
December 12, 2025 at 7:04 PM
1/ PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.
3/ PolyBio also awarded $1M to UCSF to expand the LIINC program into ME/CFS, using tissue biopsy and advanced ImmunoPET-CT imaging to study viral persistence and immune activation in the brain, spinal cord, and bone marrow.
December 11, 2025 at 1:53 AM
3/ PolyBio also awarded $1M to UCSF to expand the LIINC program into ME/CFS, using tissue biopsy and advanced ImmunoPET-CT imaging to study viral persistence and immune activation in the brain, spinal cord, and bone marrow.
How PolyBio is driving forward ME/CFS research🧵
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
December 11, 2025 at 1:53 AM
How PolyBio is driving forward ME/CFS research🧵
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.
“We sought out Amy & PolyBio because we cannot afford less than the best knowledge & information to help guide our [mAb trials],” said Invivyd chairman Marc Elia. PolyBio has funded 4+ clinical trials & most recently is supporting sample analysis for a RCT of Anktiva in Long Covid.
December 10, 2025 at 6:37 PM
“We sought out Amy & PolyBio because we cannot afford less than the best knowledge & information to help guide our [mAb trials],” said Invivyd chairman Marc Elia. PolyBio has funded 4+ clinical trials & most recently is supporting sample analysis for a RCT of Anktiva in Long Covid.